Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Operating Leases (2021 - 2025)

Historic Operating Leases for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $118.1 million.

  • Prime Medicine's Operating Leases rose 18640.18% to $118.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.1 million, marking a year-over-year increase of 18640.18%. This contributed to the annual value of $37.2 million for FY2024, which is 75333.95% up from last year.
  • Latest data reveals that Prime Medicine reported Operating Leases of $118.1 million as of Q3 2025, which was up 18640.18% from $119.7 million recorded in Q2 2025.
  • Prime Medicine's 5-year Operating Leases high stood at $121.2 million for Q1 2025, and its period low was $3.1 million during Q4 2021.
  • For the 5-year period, Prime Medicine's Operating Leases averaged around $44.9 million, with its median value being $32.5 million (2022).
  • Its Operating Leases has fluctuated over the past 5 years, first crashed by 7444.72% in 2023, then surged by 75333.95% in 2024.
  • Quarter analysis of 5 years shows Prime Medicine's Operating Leases stood at $3.1 million in 2021, then surged by 455.41% to $17.1 million in 2022, then crashed by 74.45% to $4.4 million in 2023, then surged by 753.34% to $37.2 million in 2024, then surged by 217.74% to $118.1 million in 2025.
  • Its Operating Leases stands at $118.1 million for Q3 2025, versus $119.7 million for Q2 2025 and $121.2 million for Q1 2025.